axoCells ALS Toolbox
Amyotrophic Lateral Sclerosis (ALS)
Research/Preclinical ToolsActive
Key Facts
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Research/Preclinical Tools
Status
Active
Company
About Axol Bioscience
Axol Bioscience is a leading provider of human iPSC-derived cells and contract services, operating as a critical enabler for drug discovery in human disease modeling. With over a decade of expertise, the company manufactures functional cells like cardiomyocytes and neurons and offers services including custom cell production, disease model creation, reprogramming, and gene editing. It holds ISO 9001:2015 certification for manufacturing and serves a global clientele, positioning itself at the intersection of the growing iPSC tools and services market. The company is privately held and appears to be in a revenue-generating stage, supported by its portfolio of products and collaborative projects.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| Undisclosed Program | Zhimeng Biopharma | Clinical |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |